Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80521 |
Name | lung non-squamous non-small cell carcinoma |
Definition | A lung non-small cell carcinoma that is characterized by the lack of evidence of squamous differentiation. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma lung non-squamous non-small cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ALK rearrange | Ceritinib | lung non-squamous non-small cell carcinoma | sensitive | detail... |
MAP2K1 K57N | Trametinib | lung non-squamous non-small cell carcinoma | predicted - sensitive | detail... |
FGFR2 Y375C | Erdafitinib | lung non-squamous non-small cell carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01631279 | Phase Ib/II | TH-4000 | A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors | Terminated | USA | NZL | 0 |
NCT02657434 | Phase III | Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium | A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) | Completed | USA | ROU | NLD | LVA | LTU | ITA | ISR | IRL | HUN | GBR | FRA | ESP | BGR | BEL | AUT | AUS | ARG | 10 |
NCT02810457 | Phase III | Carboplatin + FKB238 + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel | Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA) | Completed | USA | TUR | ROU | POL | ITA | HUN | HRV | GRC | ESP | DEU | BGR | 13 |
NCT02817633 | Phase I | Cobolimab Cobolimab + Dostarlimab-gxly + TSR-033 Cisplatin + Cobolimab + Dostarlimab-gxly + Pemetrexed Disodium Cobolimab + Dostarlimab-gxly Cobolimab + Nivolumab Cobolimab + Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly | A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | Recruiting | USA | ESP | 2 |
NCT03083691 | Phase II | Ipilimumab + Nivolumab | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | Completed | DEU | 0 |
NCT03267316 | Phase Ib/II | Nidanilimab Cisplatin + Gemcitabine + Nidanilimab Gemcitabine + Nab-paclitaxel + Nidanilimab | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR) | Completed | SWE | NOR | NLD | LVA | LTU | EST | ESP | DNK | DEU | BEL | AUT | 0 |
NCT03293680 | Phase II | Pembrolizumab | Pembrolizumab in Elderly Patients With Advanced Lung Cancer | Completed | ESP | 0 |
NCT03409614 | Phase III | Cemiplimab + Ipilimumab Cemiplimab | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | Active, not recruiting | USA | TUR | SVK | ROU | POL | LTU | ITA | IRL | GRC | FRA | AUT | 7 |
NCT03449381 | Phase I | BI 907828 | This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) | Active, not recruiting | USA | SWE | POL | ISR | ESP | DNK | DEU | CAN | BEL | 2 |
NCT03468426 | Phase I | BI 836880 + Ezabenlimab | A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours | Completed | USA | POL | GBR | FRA | ESP | DEU | AUS | 5 |
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |
NCT03526887 | Phase II | Pembrolizumab | Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay) | Completed | ESP | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
NCT03786692 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Bevacizumab + Carboplatin + Pemetrexed Disodium | Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC | Recruiting | USA | 0 |
NCT03896074 | Phase II | Atezolizumab + Bevacizumab Atezolizumab | Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT) | Unknown status | ITA | 0 |
NCT03906071 | Phase III | Docetaxel Nivolumab + Sitravatinib | Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE) | Active, not recruiting | USA | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BEL | 0 |
NCT03909334 | Phase II | Osimertinib + Ramucirumab Osimertinib | Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
NCT03975114 | Phase II | Durvalumab + Tremelimumab Durvalumab | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5) | Recruiting | ITA | 0 |
NCT03976323 | Phase III | Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Olaparib + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | Active, not recruiting | USA | TUR | ROU | POL | NZL | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 6 |
NCT03976375 | Phase III | Lenvatinib Lenvatinib + Pembrolizumab Docetaxel | Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) | Completed | USA | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | AUS | ARG | 6 |
NCT03994393 | Phase II | Durvalumab + Tremelimumab | Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease. (ILLUMINATE) | Active, not recruiting | AUS | 1 |
NCT04027946 | Phase II | LMB-100 + Pembrolizumab | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT04035486 | Phase III | Osimertinib Carboplatin + Osimertinib + Pemetrexed Disodium Cisplatin + Osimertinib + Pemetrexed Disodium Osimertinib + Pemetrexed Disodium | A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2) | Active, not recruiting | USA | SVK | GBR | FRA | CZE | CAN | BRA | AUS | ARG | 12 |
NCT04042558 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Pemetrexed Disodium Atezolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Cisplatin + Pemetrexed Disodium | A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018) | Recruiting | FRA | 0 |
NCT04043195 | Phase Ib/II | Ipilimumab + Nivolumab + Oxaliplatin Nivolumab + Oxaliplatin | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (NSCLC) | Active, not recruiting | USA | 0 |
NCT04084717 | Phase II | Crizotinib | Study of Crizotinib for ROS1 and MET Activated Lung Cancer | Recruiting | CAN | 0 |
NCT04093167 | Phase II | Pembrolizumab | Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC | Recruiting | USA | CAN | 0 |
NCT04099836 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib | Terminated | USA | 0 |
NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Completed | USA | 0 |
NCT04154956 | Phase III | SAR408701 Docetaxel | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03) | Active, not recruiting | USA | TUR | ROU | POL | NLD | LTU | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUS | ARG | 9 |
NCT04163432 | Phase II | Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium | Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC (STAGGER) | Recruiting | USA | 0 |
NCT04173507 | Phase II | Avelumab + Talazoparib | Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) | Completed | USA | 0 |
NCT04181060 | Phase III | Osimertinib Bevacizumab + Osimertinib | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Recruiting | USA | 0 |
NCT04194944 | Phase III | Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Selpercatinib Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) | Active, not recruiting | TUR | ROU | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT04225117 | Phase II | Enfortumab vedotin-ejfv | A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Active, not recruiting | USA | CAN | 1 |
NCT04245085 | Phase II | Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Atezolizumab + Bevacizumab + Pemetrexed Disodium | ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (ABC-lung) | Active, not recruiting | ESP | DEU | CHE | 2 |
NCT04262856 | Phase II | AB154 + Etrumadenant + Zimberelimab Zimberelimab AB154 + Zimberelimab | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) | Active, not recruiting | USA | CAN | AUS | 4 |
NCT04265534 | Phase II | Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE) | Terminated | USA | 0 |
NCT04310007 | Phase II | Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04332367 | Phase II | Carboplatin + Paclitaxel + Ramucirumab | Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance | Recruiting | USA | 0 |
NCT04351555 | Phase III | Cisplatin + Pemetrexed Disodium Cisplatin + Osimertinib + Pemetrexed Disodium Carboplatin + Osimertinib + Pemetrexed Disodium Osimertinib Carboplatin + Pemetrexed Disodium | A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA) | Active, not recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BGR | AUT | 11 |
NCT04394624 | Phase II | Ramucirumab + SAR408701 Pembrolizumab + Ramucirumab + SAR408701 | Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (CARMEN-LC04) | Terminated | USA | ESP | CZE | BGR | 2 |
NCT04432857 | Phase I | E7046 + Pembrolizumab | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Active, not recruiting | USA | FRA | 0 |
NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Terminated | USA | 0 |
NCT04447118 | Phase III | Pyrotinib Docetaxel | Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1) | Active, not recruiting | USA | TUR | POL | ITA | FRA | ESP | DEU | BEL | AUS | 4 |
NCT04470674 | Phase II | Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium Durvalumab | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (>=50%) NSCLC Patients | Withdrawn | USA | 0 |
NCT04524689 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + SAR408701 Cisplatin + Pemetrexed Disodium + SAR408701 Carboplatin + Pembrolizumab + SAR408701 Pembrolizumab + SAR408701 Cisplatin + Pembrolizumab + SAR408701 | Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05) | Active, not recruiting | USA | ISR | HUN | FRA | ESP | CZE | BRA | 1 |
NCT04538664 | Phase III | Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON) | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 12 |
NCT04563338 | Phase II | Atezolizumab Atezolizumab + Bevacizumab | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | Recruiting | CAN | 0 |
NCT04581824 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | ROU | POL | ITA | FRA | ESP | DEU | BRA | ARG | 3 |
NCT04619797 | Phase II | Atezolizumab + Pemetrexed Disodium + Tiragolumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06) | Active, not recruiting | USA | TUR | POL | NZL | ITA | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | 7 |
NCT04622774 | Phase I | IMGC936 | First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors | Completed | USA | ITA | ESP | 0 |
NCT04686305 | Phase I | MEDI5752 + Trastuzumab deruxtecan Trastuzumab deruxtecan Carboplatin + MEDI5752 + Trastuzumab deruxtecan Durvalumab + Pemetrexed Disodium + Trastuzumab deruxtecan Carboplatin + Durvalumab + Trastuzumab deruxtecan Cisplatin + Durvalumab + Trastuzumab deruxtecan | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03) | Recruiting | USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | CAN | BEL | AUS | 6 |
NCT04691817 | Phase Ib/II | Atezolizumab + Tocilizumab | Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | Recruiting | USA | 0 |
NCT04758949 | Phase II | Nivolumab FL-101 + Nivolumab FL-101 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | Withdrawn | 0 | |
NCT04765059 | Phase III | Cisplatin + Pemetrexed Disodium Cisplatin + Osimertinib + Pemetrexed Disodium Carboplatin + Osimertinib + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COMPEL) | Active, not recruiting | USA | ITA | ISR | ESP | DEU | 1 |
NCT04772235 | Phase I | Osimertinib + Repotrectinib | Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (TOTEM) | Recruiting | ESP | 0 |
NCT04786964 | Phase III | Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Cosibelimab + Pemetrexed Disodium Carboplatin + Cosibelimab + Pemetrexed Disodium | Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (CONTERNO) | Terminated | NZL | BRA | 6 |
NCT04822298 | Phase I | AMG 160 | Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer | Terminated | USA | AUT | AUS | 0 |
NCT04865250 | Phase II | Atezolizumab + Carboplatin + Nab-paclitaxel | Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (iReP) | Recruiting | DEU | 0 |
NCT04908111 | Phase Ib/II | MVA-MAGEA3 ChAdOx1-MAGEA3-NYESO | A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 | Suspended | GBR | 0 |
NCT04914897 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707 Pembrolizumab + THOR-707 Nab-paclitaxel + Pembrolizumab + THOR-707 Cisplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) | Terminated | USA | POL | ITA | FRA | ESP | AUS | ARG | 4 |
NCT04925986 | Phase II | Pembrolizumab + Sitravatinib | Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC | Terminated | USA | 0 |
NCT04928846 | Phase III | Telisotuzumab vedotin Docetaxel | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | TUR | SWE | SVK | ROU | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 8 |
NCT04956692 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | Active, not recruiting | USA | TUR | ROU | POL | HUN | FRA | ESP | BRA | 8 |
NCT04958811 | Phase II | Atezolizumab + Bevacizumab + Tiragolumab | Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC | Recruiting | USA | 0 |
NCT04971187 | Phase II | Bintrafusp alfa + Carboplatin + Pemetrexed Disodium Bintrafusp alfa + Cisplatin + Pemetrexed Disodium | Bintrafusp Alfa With Pemetrexed and Platinum-Based Chemotherapy for the Treatment of Locally Advanced or Metastatic Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT04988295 | Phase III | Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Amivantamab-vmjw + Carboplatin + Lazertinib + Pemetrexed Disodium | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2) | Active, not recruiting | USA | TUR | SWE | POL | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | ARG | 11 |
NCT04993677 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + SEA-CD40 Pembrolizumab + SEA-CD40 | A Study of SEA-CD40 Given With Other Drugs in Cancers | Active, not recruiting | USA | SWE | FRA | ESP | DEU | CAN | 0 |
NCT04995523 | Phase Ib/II | AZD2936 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01) | Active, not recruiting | USA | NLD | FRA | ESP | DNK | BRA | BEL | AUS | 6 |
NCT05017025 | Phase Ib/II | LY3295668 + Osimertinib | Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT05048797 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | Recruiting | USA | TUR | POL | NLD | ITA | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | 7 |
NCT05067283 | Phase I | MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin | A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Recruiting | USA | TUR | POL | NZL | ITA | ISR | ESP | DNK | CHE | CAN | AUS | 7 |
NCT05070247 | Phase I | TAK-500 Pembrolizumab + TAK-500 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05118854 | Phase II | Cisplatin + Pemetrexed Disodium + Sotorasib Carboplatin + Pemetrexed Disodium + Sotorasib | A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation | Recruiting | USA | 0 |
NCT05120349 | Phase III | Osimertinib | A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (ADAURA2) | Active, not recruiting | USA | TUR | ROU | POL | ITA | GBR | ESP | DEU | CAN | BRA | ARG | 9 |
NCT05170204 | Phase III | Durvalumab Alectinib Pralsetinib Entrectinib | A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 11 |
NCT05184712 | Phase III | Carboplatin + Pemetrexed Disodium Ivonescimab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Ivonescimab + Pemetrexed Disodium | Phase 3 Clinical Study of AK112 for NSCLC Patients | Active, not recruiting | 1 | |
NCT05242965 | Phase II | Sargramostim Sargramostim + STEMVAC | A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05245071 | Phase II | SAR408701 | Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (CARMEN-LC06) | Active, not recruiting | USA | TUR | ITA | FRA | ESP | BEL | 1 |
NCT05338970 | Phase III | Patritumab deruxtecan | HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy | Active, not recruiting | USA | POL | NOR | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT | AUS | 7 |
NCT05358548 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab | ATATcH Alternating Treatment Plans for Advanced Cancer | Recruiting | USA | 0 |
NCT05394675 | Phase I | DS-9606a | A Study of DS-9606a in Patients With Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
NCT05400577 | Phase II | Sotorasib | Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC | Withdrawn | USA | 0 |
NCT05401110 | Phase I | Carotuximab + Osimertinib | Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05403385 | Phase II | Carboplatin + EOS100850 + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | 0 |
NCT05403554 | Phase I | NI-1801 | A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers | Recruiting | ITA | FRA | 0 |
NCT05429762 | Phase I | SAR408701 | Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (TusaRav-QT) | Terminated | USA | TUR | FRA | ESP | BEL | 0 |
NCT05469178 | Phase Ib/II | Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium | A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05492682 | Phase I | Cyclophosphamide + Pembrolizumab + PeptiCRAd-1 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | Recruiting | DEU | 0 |
NCT05513703 | Phase II | Telisotuzumab vedotin | A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | ITA | ISR | FRA | DEU | AUS | 3 |
NCT05557591 | Phase II | Cemiplimab BNT116 + Cemiplimab | A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) | Recruiting | USA | TUR | ESP | DEU | 3 |
NCT05567055 | Phase II | Capmatinib | Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations | Withdrawn | 0 | |
NCT05601973 | Phase II | Amivantamab-vmjw + Bevacizumab + Lazertinib | AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (AMAZE-lung) | Recruiting | NLD | ITA | GBR | FRA | ESP | CHE | 0 |
NCT05607550 | Phase III | Cisplatin + Pemetrexed Disodium Furmonertinib Carboplatin + Pemetrexed Disodium | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) | Recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | CAN | BRA | AUS | 9 |
NCT05650879 | Phase I | ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002 | ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2) | Recruiting | USA | ITA | FRA | ESP | AUS | 2 |
NCT05652868 | Phase I | MYTX-011 | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer | Recruiting | USA | GBR | FRA | ESP | AUS | 2 |
NCT05668988 | Phase III | Sunvozertinib Carboplatin + Pemetrexed Disodium | A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) | Recruiting | USA | TUR | POL | NLD | ITA | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 1 |
NCT05689671 | FDA approved | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Nab-paclitaxel | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma (ANTELOPE) | Recruiting | DEU | 0 |
NCT05692999 | Phase III | Pembrolizumab + Pemetrexed Disodium | Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study (Pulse) | Recruiting | FRA | 0 |
NCT05703555 | Phase II | SAR408701 | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 (INTRUSION) | Withdrawn | NLD | 0 |
NCT05704634 | Phase I | Cemiplimab + Sarilumab | A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. | Recruiting | USA | 0 |
NCT05746481 | Phase II | Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab | Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases | Recruiting | USA | 0 |
NCT05769959 | Phase Ib/II | RO7515629 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Terminated | USA | 0 |
NCT05800015 | Phase II | Cemiplimab + Cisplatin + Fianlimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Fianlimab + Paclitaxel Cemiplimab + Cisplatin + Paclitaxel Carboplatin + Cemiplimab + Paclitaxel | A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | Recruiting | USA | ISR | CAN | AUS | 4 |
NCT05801029 | Phase II | Amivantamab-vmjw + Osimertinib | A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (OSTARA) | Recruiting | USA | CAN | 6 |
NCT05865990 | Phase II | Patritumab deruxtecan | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3) | Active, not recruiting | ESP | AUT | 0 |
NCT05882734 | Phase Ib/II | Cemiplimab + M1774 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | 2 |
NCT05902988 | Phase Ib/II | VLS-1488 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Recruiting | USA | 0 |
NCT05920356 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Sotorasib | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Recruiting | USA | TUR | SWE | ROU | POL | NLD | LVA | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 12 |
NCT05973773 | Phase III | Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Zipalertinib Carboplatin + Pemetrexed Disodium + Zipalertinib Pemetrexed Disodium Cisplatin + Pemetrexed Disodium + Zipalertinib | REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3) | Recruiting | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | BEL | 4 |
NCT06003075 | Phase II | Carboplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Gemcitabine + Nivolumab | Induction Chemo-Nivo in Unresectable Stage III NSCLC | Terminated | USA | 0 |
NCT06008093 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON) | Recruiting | USA | 0 |
NCT06074588 | Phase III | Docetaxel SKB264 Pemetrexed Disodium | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Recruiting | USA | TUR | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | 10 |
NCT06119581 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium | A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01) | Recruiting | USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 7 |
NCT06120075 | Phase I | AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) | Recruiting | USA | 0 |
NCT06151574 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Zongertinib | Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | Recruiting | USA | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | ARG | 6 |
NCT06170788 | Phase III | Pembrolizumab + SKB264 Pembrolizumab | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >= 50% (MK-2870-007) | Recruiting | USA | TUR | POL | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | AUS | ARG | 9 |
NCT06173505 | Phase Ib/II | Carboplatin + Pemetrexed Disodium + XmAb20717 Carboplatin + Pembrolizumab + Pemetrexed Disodium | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | Recruiting | USA | NLD | ESP | BEL | 2 |
NCT06216301 | Phase III | Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (LUNAR-2) | Recruiting | USA | 0 |
NCT06236438 | Phase II | ABBV-151 + Budigalimab + Cisplatin + Pemetrexed Disodium Budigalimab + Carboplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium ABBV-151 + Budigalimab + Carboplatin + Pemetrexed Disodium ABBV-151 + Budigalimab + Pemetrexed Disodium Budigalimab + Cisplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium | Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4) | Recruiting | USA | TUR | ISR | AUS | 3 |
NCT06244485 | Phase I | DS-3201b + Trastuzumab deruxtecan Datopotamab deruxtecan + DS-3201b | A Study of Valemetostat in Combination With DXd ADCs in Subjects With Solid Tumors | Recruiting | USA | 1 |
NCT06279728 | Expanded access | Datopotamab deruxtecan | Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients | Available | USA | ESP | DEU | CHE | CAN | AUT | 1 |
NCT06305754 | Phase III | Carboplatin + Pemetrexed Disodium SKB264 | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | Recruiting | USA | SWE | POL | ITA | FRA | ESP | CAN | ARG | 4 |
NCT06311721 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab ABP 234 + Cisplatin + Pemetrexed Disodium ABP 234 + Carboplatin + Pemetrexed Disodium ABP 234 + Pemetrexed Disodium | A Study to Compare ABP 234 and Keytruda (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | Recruiting | USA | ROU | POL | ITA | HUN | ESP | BGR | 5 |
NCT06312137 | Phase III | Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab + SKB264 | A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | Recruiting | USA | ROU | POL | NOR | NLD | ISR | GRC | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
NCT06330064 | Phase II | Ifinatamab deruxtecan | A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Recruiting | USA | TUR | POL | NLD | ITA | IRL | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 5 |
NCT06348199 | Phase III | Pembrolizumab Carboplatin + Pemetrexed Disodium | A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer | Recruiting | TUR | ROU | ESP | DEU | BRA | 9 |
NCT06350097 | Phase III | Osimertinib Datopotamab deruxtecan + Osimertinib | Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14) | Recruiting | USA | POL | ITA | ESP | DEU | CAN | BRA | AUS | 7 |
NCT06357533 | Phase III | Pembrolizumab AZD2936 + Datopotamab deruxtecan AZD2936 | Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC >= 50%) and Without Actionable Genomic Alterations (TROPION-Lung10) | Recruiting | USA | TUR | POL | ITA | HUN | GBR | ESP | DEU | CAN | BRA | BEL | AUT | AUS | 6 |
NCT06396065 | Phase III | Carboplatin + Pemetrexed Disodium Carboplatin + Ivonescimab + Paclitaxel | Phase III Study of AK112 for NSCLC Patients | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT06401824 | Phase II | Bevacizumab + Sacituzumab govitecan-hziy | Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases | Not yet recruiting | NLD | 0 |
NCT06417814 | Phase III | Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Datopotamab deruxtecan + Osimertinib Datopotamab deruxtecan | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15) | Recruiting | USA | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 10 |
NCT06448754 | Phase II | Carboplatin + MEDI5752 + Pemetrexed Disodium | Volrustomig Priming Regimens Exploratory Phase II Platform Study (eVOLVE-01) | Recruiting | USA | ITA | FRA | ESP | CHE | CAN | 7 |
NCT06452277 | Phase III | BAY2927088 Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium | A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02) | Recruiting | USA | TUR | SWE | SVK | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 10 |
NCT06463665 | Phase II | Cisplatin + GL-ONC1 + Nivolumab + Pemetrexed Disodium Cisplatin + GL-ONC1 + Nab-paclitaxel + Nivolumab Cisplatin + GL-ONC1 + Nivolumab + Paclitaxel Carboplatin + GL-ONC1 + Nivolumab + Pemetrexed Disodium Docetaxel Cemiplimab + Cisplatin + GL-ONC1 + Paclitaxel Carboplatin + Cemiplimab + GL-ONC1 + Pemetrexed Disodium Carboplatin + Cemiplimab + GL-ONC1 + Nab-paclitaxel Carboplatin + Cemiplimab + GL-ONC1 + Paclitaxel Atezolizumab + Carboplatin + GL-ONC1 + Nab-paclitaxel Atezolizumab + Carboplatin + GL-ONC1 + Paclitaxel Cemiplimab + Cisplatin + GL-ONC1 + Pemetrexed Disodium Cemiplimab + Cisplatin + GL-ONC1 + Nab-paclitaxel Atezolizumab + Cisplatin + GL-ONC1 + Pemetrexed Disodium Atezolizumab + Cisplatin + GL-ONC1 + Nab-paclitaxel Atezolizumab + Cisplatin + GL-ONC1 + Paclitaxel Atezolizumab + Carboplatin + GL-ONC1 + Pemetrexed Disodium Carboplatin + Durvalumab + GL-ONC1 + Pemetrexed Disodium Carboplatin + Durvalumab + GL-ONC1 + Nab-paclitaxel Carboplatin + Durvalumab + GL-ONC1 + Paclitaxel Cisplatin + Durvalumab + GL-ONC1 + Pemetrexed Disodium Cisplatin + Durvalumab + GL-ONC1 + Nab-paclitaxel Cisplatin + Durvalumab + GL-ONC1 + Paclitaxel Cisplatin + GL-ONC1 + Paclitaxel + Pembrolizumab Carboplatin + GL-ONC1 + Pembrolizumab + Pemetrexed Disodium Carboplatin + GL-ONC1 + Nab-paclitaxel + Pembrolizumab Carboplatin + GL-ONC1 + Paclitaxel + Pembrolizumab Carboplatin + GL-ONC1 + Nab-paclitaxel + Nivolumab Carboplatin + GL-ONC1 + Nivolumab + Paclitaxel Cisplatin + GL-ONC1 + Pembrolizumab + Pemetrexed Disodium Cisplatin + GL-ONC1 + Nab-paclitaxel + Pembrolizumab | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) ((VIRO-25)) | Recruiting | USA | 0 |
NCT06470763 | Phase Ib/II | ANV600 ANV600 + Pembrolizumab | A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | Recruiting | USA | NLD | FRA | ESP | DEU | CHE | 0 |
NCT06472245 | Phase III | OSE 2101 Docetaxel | Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA) | Not yet recruiting | USA | 0 |
NCT06555263 | Phase II | Luveltamab Tazevibulin | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06561386 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium + Relatlimab | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (RELATIVITY1093) | Recruiting | USA | ROU | POL | NLD | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CHE | BRA | BEL | AUT | AUS | ARG | 7 |
NCT06627647 | Phase III | AZD2936 + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium AZD2936 + Cisplatin + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | Not yet recruiting | USA | TUR | HUN | GBR | ESP | DEU | CAN | BRA | BEL | ARG | 7 |